These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26301067)

  • 1. European Union pharmacovigilance capabilities: potential for the new legislation.
    Borg JJ; Tanti A; Kouvelas D; Lungu C; Pirozynski M; Serracino-Inglott A; Aislaitner G
    Ther Adv Drug Saf; 2015 Aug; 6(4):120-40. PubMed ID: 26301067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
    Lam S
    Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in pharmaceutical companies: An overview.
    Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
    Inácio P; Cavaco A; Allan E; Airaksinen M
    Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use.
    Santoro A; Caplanusi I; Sweeney F; Cappelli B; Nolan L; Straus S; Arlett P
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1343-1352. PubMed ID: 32954565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in Italy: An overview.
    Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
    Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
    Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.